The Company is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.


Updates from The Motley Fool

Latest updates on Illumina from Fool.com.  The Fool has written over 300 articles on Illumina.
Why Illumina Is a Buy

The gene sequencing pioneer is undeniably expensive -- and yet still undeniably attractive.

Illumina Lights It Up

News of a new family of sequencers got the market excited this week -- with good reason.

3 Top Growth Stocks for 2017

Motley Fool Explorer lead advisor Simon Erickson shares three stocks that he expects to outperfor...



Stock Performance

View Interactive ILMN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Illumina.
Current Price: $163.37
Prev Close: $161.30
Open: $161.30
Bid: $155.00
Ask: $170.00
Day's Range: $161.12 - $163.46
52wk Range: $119.37 - $186.88
Volume: 892,449
Avg Vol 1,301,691
Market Cap: $24B
P/E (ttm): 52.54
EPS (ttm): $3.07
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Illumina.
CAPS Rating 5 out of 5
 
1104 Outperform
53 Underperform
CAPS All Stars
 
297 Outperform
11 Underperform

How do you think Illumina will perform against the market?



You pick for Illumina is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Francis deSouza, CEO

87% Approve

Based on 46 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Illumina.

The Company is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers